Use of HIV Recency Assays for HIV Incidence Estimation and Other Surveillance Use Cases: Systematic Review

Journals

1. Kin-On Lau J, Murdock N, Murray J, Justman J, Parkin N, Miller V. A systematic review of limiting antigen avidity enzyme immunoassay for detection of recent HIV-1 infection to expand supported applications. Journal of Virus Eradication 2022;8(3):100085 View
2. Nikolopoulos G, Tsantes A. Recent HIV Infection: Diagnosis and Public Health Implications. Diagnostics 2022;12(11):2657 View
3. Sokhela S, Lalla-Edward S, Siedner M, Majam M, Venter W. Roadmap for Achieving Universal Antiretroviral Treatment. Annual Review of Pharmacology and Toxicology 2023;63(1):99 View
4. Mohloanyane T, Olivier D, Labhardt N, Amstutz A, Lessells R. Recent HIV infections among newly diagnosed individuals living with HIV in rural Lesotho: Secondary data from the VIBRA cluster-randomized trial. PLOS ONE 2022;17(11):e0277812 View
5. Parkin N, Gao F, Grebe E, Cutrell A, Das M, Donnell D, Duerr A, Glidden D, Hughes J, Murray J, Robertson M, Zinserling J, Lau J, Miller V. Facilitating Next‐Generation Pre‐Exposure Prophylaxis Clinical Trials Using HIV Recent Infection Assays: A Consensus Statement from the Forum HIV Prevention Trial Design Project. Clinical Pharmacology & Therapeutics 2023;114(1):29 View
6. Suthar A, Ouk V, Samreth S, Ngauv B, Bain R, Eng B, Hy C, Ernst A, Rutherford G, Yang C, Ly V, Albalak R. Programmatic Implications of National Recent HIV Infection Surveillance in Cambodia. The Journal of Infectious Diseases 2023;228(10):1347 View
7. Faraci G, Park S, Love T, Dubé M, Lee H, Chao D. Precision detection of recent HIV infections using high-throughput genomic incidence assay. Microbiology Spectrum 2023;11(5) View
8. Sharma I, Hill A. Global HIV Incidence Analysis and Implications for Affordability Using Long-Acting Cabotegravir Versus Continuous and Event-Driven Oral Preexposure Prophylaxis. Clinical Infectious Diseases 2024;78(2):386 View
9. Torres T, Teixeira S, Hoagland B, Konda K, Derrico M, Moreira R, Guanira J, Benedetti M, Nazer S, Calvo G, Vargas S, Benites C, Bigolin Á, Alonso Neto J, Farias A, Guimarães Lacerda M, Raenck Silva D, Paz L, Madruga J, Salvatierra Flores H, Boluarte G, Osco Tamayo C, Castro Antezana H, Pimenta M, Bórquez A, Luz P, Grinsztejn B, Szwarcwald C, Cáceres C, Veloso V, Kristic T, Rocha C, da Silva Santos W, Lovreto Santana A, Lima R, Souza C, Oliva T, Valões M, Olivetto J, Mota G, Cano A, Trefiglio R, Coutinho C, Elorreaga O, Gutierrez X, Olivos F, Caviedes D, Adriazola D, Juárez E, Mariño G, Qquellon J, Vasquez F, Jiron J, Flores S, Campos K, Eguiluz M. Recent HIV infection and annualized HIV incidence rates among sexual and gender minorities in Brazil and Peru (ImPrEP seroincidence study): a cross-sectional, multicenter study. The Lancet Regional Health - Americas 2023;28:100642 View
10. Donnell D, Kansiime S, Glidden D, Luedtke A, Gilbert P, Gao F, Janes H. Study design approaches for future active-controlled HIV prevention trials. Statistical Communications in Infectious Diseases 2023;15(1) View
11. van den Berg K, Murphy E, Maartens G, Louw V, Grebe E. The impact of non‐disclosure of HIV status and antiretroviral therapy on HIV recency testing and incidence algorithms. Vox Sanguinis 2024;119(6):581 View
12. Di Germanio C, Deng X, Grebe E, Johnson J, Masciotra S, Busch M, Norris P. Performance of a rapid recency assay for detection of early HIV infection. Journal of Clinical Virology 2024;174:105708 View
13. Beyrer C, Tomaras G, Gelderblom H, Gray G, Janes H, Bekker L, Millett G, Pantaleo G, Buchbinder S, Corey L. Is HIV epidemic control by 2030 realistic?. The Lancet HIV 2024;11(7):e489 View
14. Sharma M, Mambo B, Kingston H, Otieno G, Masyuko S, Lagat H, Katz D, Wamuti B, Macharia P, Bosire R, Mugambi M, Kariithi E, Farquhar C. Providing HIV‐assisted partner services to partners of partners in western Kenya: an implementation science study. Journal of the International AIDS Society 2024;27(S1) View